The DOI matches its Crossref record.
Topical treatment of actinic keratoses with 3·0% diclofenac in 2·5% hyaluronan gel: TOPICAL DICLOFENAC FOR AK
Abstract
BACKGROUND: Actinic keratoses (AKs) are premalignant skin lesions, which, if left untreated, can develop into squamous cell carcinoma. Current treatments for AKs are destructive and are often associated with significant adverse events. The development of an effective and well-tolerated topical treatment for AK is desirable. OBJECTIVES: To evaluate the efficacy and safety of 3.0% diclofenac in 2.5% hyaluronan gel as a treatment for AK. METHODS: This was a multicentre, double-blind, placebo-controlled study in which 195 patients with at least five AKs in up to three designated treatment blocks were randomized to four treatment groups. Patients randomized into the active treatment groups A30 (n = 49) and A60 (n = 48) received topical treatment with 3.0% diclofenac in 2.5% hyaluronan gel 0.5 g twice daily for 30 or 60 days, respectively. Patients in the placebo (vehicle gel) groups V30 (n = 49) and V60 (n = 49) received topical treatment with 2.5% hyaluronan gel 0.5 g twice daily for 30 or 60 days, respectively. Treatment efficacy was assessed by target and cumulative lesion number scores (TLNS and CLNS, respectively) and lesion total thickness score (TTS). Investigator and patient global improvement indices (IGII and PGII) were also used to rate overall improvement. RESULTS: Compared with placebo, significantly more patients given active treatment for 60 days had TLNS = 0 (33% vs. 10%, P < 0.05; an improvement of 64% compared with 34% with placebo), CLNS = 0 (31% vs. 8%, P < 0.05; an improvement of 54% compared with 23% with placebo) and TTS = 0 (25% vs. 6%, P < 0.05; an improvement of 59% compared with 31% with placebo). The IGII and PGII scores were also significantly better when active treatment was compared with placebo (P < 0.05). Both treatments were generally well tolerated and the incidence of the most common adverse events was similar between groups. CONCLUSIONS: Treatment with 3.0% diclofenac in 2.5% hyaluronan gel was effective when used for 60 days and was well tolerated in patients with AK.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ingenol Mebutate Gel for Actinic Keratosis
Lebwohl, M., Swanson, N., Anderson, L. L., Melgaard, A., Xu, Z., & Berman, B. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111170 · Cited by 471
Guidelines for the management of actinic keratoses
de Berker, D., McGregor, J. M., Hughes, B. R., & on behalf of the British Association of Dermatologists Therapy Guidelines and Audit Subcommittee (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07692.x · Cited by 296
Skin cancer prevention: a review of current topical options complementary to sunscreens
Rosenthal, A., Stoddard, M., Chipps, L., & Herrmann, J. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15522 · Cited by 28
Metadata
- Authors
- Rivers, J. K., Arlette, J., Shear, N., Guenther, L., Carey, W., & Poulin, Y.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-01
- Volume
- 146
- Issue
- 1
- Pages
- 94-100
- ISSN
- 0007-0963 (ISSN-L)
- OpenAlex
- W1895525610
- Cited by
- 215
- References
- 0
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Topical treatment of actinic keratoses with 3·0% diclofenac in 2·5% hyaluronan gel: TOPICAL DICLOFENAC FOR AK. https://app.cochat.ai/papers/10.1046/j.1365-2133.2002.04561.x
- The paper
- Rivers, J. K., Arlette, J., Shear, N., Guenther, L., Carey, W., & Poulin, Y. (2002). Topical treatment of actinic keratoses with 3·0% diclofenac in 2·5% hyaluronan gel: TOPICAL DICLOFENAC FOR AK. British Journal of Dermatology. https://doi.org/10.1046/j.1365-2133.2002.04561.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.